Astra Zeneca will utilize the Proteome-SEQ service from Biognosys

Biognosys’ Proteome-SEQ is a comprehensive standardized discovery service for precise quantification of 1000s of proteins in parallel across multiple samples. The service now used by Astra Zeneca addresses research questions where identification of specific protein expression differences against the backdrop of the whole proteome is important. Examples for applications are drug target discovery and biomarker development. Proteome-SEQ is optimized for different sample types including human tissues and is based on the Hyper Reaction Monitoring (HRM) technology.

HRM-MS is a next-generation mass spectrometric technology developed by Biognosys that provides reproducible and accurate quantification of 1000s of proteins in a single instrument run and in many aspects resembles next-gen sequencing in the RNA or DNA field. HRM outperforms any other proteomics technique for quantification of large number of proteins and does not require time consuming method development which is a limiting factor with classical affinity based approaches.

HRM is based on data-independent acquisition (DIA or SWATH) which collects all detectable ion signals in a single instrument run. These ion maps are then queried with Biognosys powerful signal processing software Spectronaut™ using pre-developed reference assay libraries. Biognosys uses a patent protected method for high-content and high-quality library generation that results in superior specificity and sensitivity compared to public assay repositories.

About Biognosys
Biognosys is the leading proteomics company offering services and products for highly multiplexed protein quantification. Founded in 2008 as spin-off from the lab of proteomics pioneer Ruedi Aebersold at ETH Zurich, Biognosys is dedicated to transform life science with superior technology and software.